News | February 27, 2015

Decipher Prostate Cancer Test Found to Predict Benefits of Radiation Therapy Following Surgery

Test could help identify high-risk patients needing therapy, low-risk patients who can wait

GenomeDx Biosciences, Decipher, prostate cancer, radiation therapy, test

February 27, 2015 — GenomeDx Biosciences announced the publication of a positive validation study for the Decipher Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy. The identification of the right patients for post-operative radiation therapy and the timing of administering that therapy are not easily answered by clinical risk factors alone.

The study was conducted by researchers from Thomas Jefferson University and Mayo Clinic. This is the eighth publication of a positive validation study for the Decipher Prostate Cancer test.

"The optimal timing of post-prostatectomy radiation therapy is a subject of debate," says Robert Den, M.D., of the Sidney Kimmel Medical College of Thomas Jefferson University and lead author of the study. "Common practice is to wait for prostate-specific antigen (PSA) rise after surgery before intervening with radiation treatment. The results of this study suggest that we can use a genomic test to identify a group of men who will benefit from earlier administration of additional local treatment."

Current clinical practice guidelines from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) recommend physicians offer adjuvant radiotherapy after surgery for men who have been diagnosed with intermediate and high-risk prostate cancer. These recommendations are based on evidence from multiple randomized clinical trials, which demonstrated the efficacy of earlier, or adjuvant radiotherapy with reductions in recurrence and progression as compared to a "wait-and-see" approach after surgery. However, not all men receive a benefit from early radiation therapy, and there is an obvious need to identify patients who will and won't benefit, so as to avoid overtreatment and serious side effects such as incontinence, impotence, and rectal bleeding.

According to the AUA, adjuvant radiation therapy is administered because of adverse pathology after radical prostatectomy, while salvage radiation therapy refers to initiation of radiation therapy only after PSA rise, commonly referred to as biochemical recurrence. Until now, clinicians have used pathology and clinical risk factors, which are less accurate measures of metastatic risk, to select men appropriate for treatment with radiation therapy.

The introduction of Decipher into clinical practice means that physicians are now equipped with a tool that allows them to individualize management and better identify those who may actually benefit from early radiation and those who may safely delay treatment and avoid adverse side effects. Recently, the American Society of Clinical Oncology (ASCO) guidelines endorsed the AUA recommendation, but caveat that "not all men with adverse pathology are at equal risk for recurrence." The National Comprehensive Cancer Network prostate cancer guidelines further recommend "tumor-based molecular assays to better stratify patient risk" and selection of adjuvant therapy.

"We've known Decipher's prognostic capability from earlier research, and with this research, we were able to demonstrate that there's a predictive component as well," says R. Jeffrey Karnes, M.D., associate professor and vice chair in Urology at Mayo Clinic and an investigator on the study. "Determining the right patient and the right time for radiation therapy is not straightforward. Patients have to balance the potential complications from radiation treatment with the risk of prostate cancer recurring. This test may enhance our ability in deciding who should or should not be considered for adjuvant radiation versus close monitoring."

The study, entitled, "A Genomic Classifier Identifies Men with Adverse Pathology after Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy," included 188 prostate cancer patients who received radiation therapy after prostate surgery at Thomas Jefferson University and Mayo Clinic between 1990 and 2009. Decipher validated as the top risk factor for metastasis with 83 percent accuracy for predicting metastasis and stratifying patients with low, average, and high genomic risk with 0 percent, 9 percent and 29 percent five-year cumulative incidence of metastasis (p=0.002).

The study found that Decipher may predict benefit from radiation therapy: Patients with average-to-high Decipher risk who were treated with the more aggressive adjuvant radiation therapy had a five-year metastasis incidence of only 6 percent compared to 23 percent (p=0.008) for those who waited for PSA recurrence to trigger initiation of salvage therapy.

Overall, patients with higher Decipher results who received adjuvant radiation had an 80 percent reduction in risk of metastasis compared to those who received salvage radiation (HR: 0.20, 95% CI, p<0.04). In addition, the study found no disadvantage for salvage therapy in men with low-risk Decipher results, suggesting that these men may improve quality of life by waiting for possible PSA rise rather than taking a course of immediate radiation therapy after radical surgery.

For more information: www.deciphertest.com

Related Content

Brain Imaging Predicts Language Learning in Deaf Children
News | Magnetic Resonance Imaging (MRI) | January 23, 2018
January 23, 2018 – In a new international collaborative...
Imricor Announces Enrollment Completion for Clinical Study on Vision-MR Ablation Catheter
News | Interventional Radiology | January 23, 2018
January 23, 2018 – Imricor Medical Systems announced completion of enrollment for the...
ASTRO and ASCO Launch New Cancer Care Quality Registry
News | Radiation Therapy | January 22, 2018
January 22, 2018 — A registry that tracks the quality of medical care provided to patients receiving cancer treatment
First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Minimally Invasive Treatment Provides Relief from Back Pain

Lumbar spine MRI showing disc herniation and nerve root at baseline and one month after treatment

News | Interventional Radiology | January 11, 2018
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back...
Overlay Init